Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.47 |
| ▸ | CLPP | Q16740 | 2/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | MC5R | P33032 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982960 | 0.85 | LIMK1 (0.61) | KMT2ALIMK1MEN1DHFRNPC1 | |
| SCHEMBL4989378 | 0.82 | LIMK1 (0.51) | KMT2ALIMK1MEN1DHFR | |
| SCHEMBL4984842 | 0.82 | MEN1 (0.48) | KMT2ALIMK1CLPPMEN1 | |
| SCHEMBL4993341 | 0.82 | MEN1 (0.51) | KMT2ALIMK1CLPPMEN1DHFR | |
| SCHEMBL4989472 | 0.82 | LIMK1 (0.42) | KMT2ALIMK1MEN1DHFR | |
| SCHEMBL4986729 | 0.82 | ALDH1A1 (0.49) | KMT2ALIMK1MEN1 | |
| SCHEMBL4992362 | 0.81 | LIMK1 (0.48) | KMT2ALIMK1MEN1 | |
| SCHEMBL4986127 | 0.81 | LIMK1 (0.47) | LIMK1CLPP | |
| SCHEMBL4988843 | 0.81 | ALDH1A1 (0.47) | KMT2ALIMK1CLPPMEN1 | |
| SCHEMBL4986172 | 0.81 | SMN1; SMN2 (0.47) | KMT2ALIMK1CLPPMEN1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | KMT2A 4614/4885LIMK1 1960/4885CLPP 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.